We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Julie Lauffenburger PharmD, PhD

Julie C Lauffenburger PharmD, PhD

Instructor, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School; Assistant Director, Center for Healthcare Delivery Sciences, Brigham and Women’s Hospital; Instructor, Harvard T.H. Chan School of Public Health, Boston, MA

Julie Lauffenburger, PharmD, PhD, is an Instructor in Medicine at Harvard Medical School and the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital. She is also an Instructor in the Department of Epidemiology at Harvard T.H. Chan School of Public Health and a practicing pharmacist at the Brigham and Women’s Hospital. She is the Assistant Director of the Center for Healthcare Delivery Sciences. Her research focuses on improving medication use, adherence, and healthcare delivery in patients with common chronic diseases, particularly through the development and evaluation of patient-oriented behavioral interventions. She has extensive experience and publications using methods including pragmatic trials, predictive analytics and observational study designs in large healthcare databases. She is a Principal Investigator of research projects funded by the National Institutes of Health and the National Institute for Health Care Management.


Disclosures: Dr. Lauffenburger has received unrestricted research funding payable to her institution from AstraZeneca and Sanofi, U.S.